Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06150781 · ClinicalTrials.gov registry record
Aimovig Pregnancy Exposure Registry
A clinical trial of Migraine, sponsored by Amgen.
- Recruiting
- Registry status
- 2,842
- Enrollment target
- 1
- Study location
NCT06150781: Recruiting study of Migraine, sponsored by Amgen.
NCT06150781 is a study of Migraine that is actively recruiting participants, run by Amgen. The registered enrollment target is 2,842 participants, above the 330-participant average among 102 other Migraine trials with a reported enrollment target (761% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06150781, a study of Migraine, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- 2,842 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of women with migraine unexposed to erenumeb-aooe.
Conditions Studied
Interventions
- DRUG erenumab-aooe
Study Locations (1)
North Carolina
- IQVIA Virtual Site - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,842 participants |
| Start Date | 2021-01-27 |
| Est. Completion | 2027-10-28 |
What NCT06150781 shows while recruiting
NCT06150781 is an observational study that tracks outcomes without assigning an intervention. Its 2,842 participants enrollment target places it among the larger protocols in the corpus, above the 330-participant average among 102 other Migraine trials with a reported enrollment target (761% higher).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which erenumab-aooe is the first listed.
NCT06150781 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06150781 about?
NCT06150781 is a clinical study titled "Aimovig Pregnancy Exposure Registry". The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of women with migraine unexposed to erenumeb-aooe.
What is the current status of trial NCT06150781?
This trial is currently recruiting. The enrollment target is 2,842 participants. The study started on 2021-01-27. Estimated completion is 2027-10-28.
What conditions does trial NCT06150781 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT06150781?
The interventions under investigation include: erenumab-aooe (DRUG).
Who is sponsoring clinical trial NCT06150781?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06150781 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06150781's enrollment target sits among peer trials
2,842 1st of 102 higher than 102 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents
RECRUITING
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
Mechanistic Studies of Psilocybin in Headache Disorders
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02273297 · 2,821 participants
Healthy Start: Exploring the Fuel-mediated Programming of Neonatal Growth
- NCT06351085 · 2,869 participants · NA
Enhancing Lung Cancer Screening Through Human-Centered Intervention
- NCT05624450 · 2,870 participants · Phase 3
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
- NCT05932602 · 2,812 participants
AVEIR DR Coverage With Evidence Development (CED) Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI